Osteogenic differentiation of human induced pluripotent stem cell in the presence of testosterone and 17 β-estradiol in vitro

Yarmohammadi, Reyhaneh; Ghollasi, Marzieh; Kheirollahzadeh, Fatemeh; Soltanyzadeh, Maryam; Heshmati, Masoumeh; Amirkhani, Mohammad Amir

doi:10.1007/s11626-022-00652-3

Cited by 1 publication

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study used a physiological dose of 0.1 nM and infraphysiological dose of 1 nM [41]. In another study, the dosages of 17β-estradiol used were 10, 50, 100, 500, 1, 10, and 50 mM [47]. The least effective concentration of 17β-estradiol that could promote potent anti-inflammatory properties in the mesenchymal stem cell population was 100 nM [48].…”

Section: Discussionmentioning

confidence: 99%

“…Combination therapy was applied to enhance functionality. The applications of 17βestradiol and testosterone led to increased alkaline phosphatase activity, calcium composition, and osteogenic-related gene and protein expressions [47]. Additionally, 17β-estradiol can upregulate the expression of growth factors, such as the insulin-like growth factor-1, which further promotes osteoblast differentiation and bone formation [54].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of 17β-Estradiol on the Shape, Survival, Osteogenic Transformation, and mRNA Expression of Gingiva-Derived Stem Cell Spheroids

Kim,

Lee,

Song

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: Mesenchymal stem cells hold promise for tissue regeneration, given their robust growth and versatile differentiation capabilities. An analysis of bone marrow-sourced mesenchymal stem cell proliferation showed that 17β-estradiol could enhance their growth. This study aims to investigate the influence of 17β-estradiol on the shape, survival, osteogenic differentiation, and mineralization of human mesenchymal stem cells. Materials and Methods: Spheroids made from human gingiva-derived stem cells were cultivated with varying concentrations of 17β-estradiol: 0, 0.01, 0.1, 1, and 10 nM. Morphology was assessed on days 1, 3, and 5. The live/dead kit assay was employed on day 3 for qualitative cell viability, while cell counting kit-8 was used for quantitative viability assessments on days 1, 3, and 5. To evaluate the osteogenic differentiation of the spheroids, a real-time polymerase chain reaction assessed the expressions of RUNX2 and COL1A1 on day 7. Results: The stem cells formed cohesive spheroids, and the inclusion of 17β-estradiol did not noticeably alter their shape. The spheroid diameter remained consistent across concentrations of 0, 0.01, 0.1, 1, and 10 nM of 17β-estradiol. However, cellular viability was boosted with the addition of 1 and 10 nM of 17β-estradiol. The highest expression levels for RUNX2 and COL1A1 were observed with the introduction of 17β-estradiol at 0.1 nM. Conclusions: In conclusion, from the results obtained, it can be inferred that 17β-estradiol can be utilized for differentiating stem cell spheroids. Furthermore, the localized and controlled use, potentially through localized delivery systems or biomaterials, can be an area of active research. While 17β-estradiol holds promise for enhancing stem cell applications, any clinical use requires a thorough understanding of its mechanisms, careful control of its dosage and delivery, and extensive testing to ensure safety and efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%